(Q37579212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

Fighting tuberculosis: old drugs, new formulations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Stefano Giovagnoli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Maurizio Ricci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Aurélie Schoubben

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Carlo Rossi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Delivery

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

977-993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19678791%20AND%20SRC:MED&resulttype=core&format=json

Historical perspectives on the etiology of tuberculosis.

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Who puts the tubercle in tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Trehalose 6,6'-dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

A terminological controversy: do disseminated and miliary tuberculosis mean the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Nonreplicating persistence of mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

A replication clock for Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

DNA vaccines for therapy of tuberculosis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Current status and future prospects for new therapies for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Programmes and principles in treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Towards new tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

A novel solid dosage form of rifampicin and isoniazid with improved functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

International standards for tuberculosis care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Prospects for new antitubercular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Antitubercular inhaled therapy: opportunities, progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Adjuvant effect of biodegradable poly(DL-lactic acid) granules capable for antigen release following intraperitoneal injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Microparticles and nanoparticles for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Airways delivery of rifampicin microparticles for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Inhalable microparticles containing large payload of anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Trojan particles: large porous carriers of nanoparticles for drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Liposome technology for drug delivery against mycobacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Distribution of liposomes in tuberculous mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Tuftsin-bearing liposomes in treatment of macrophage-based infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Liposomal aerosols in the management of pulmonary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Nebulization of liposome encapsulated antitubercular drugs in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Nanotechnology: intelligent design to treat complex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

The activity of low-clearance liposomal amikacin in experimental murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Oral solid lipid nanoparticle-based antitubercular chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Body distribution of camptothecin solid lipid nanoparticles after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Drying a tuberculosis vaccine without freezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Immunization by a bacterial aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577

Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903130577